DAVENPORT & Co LLC Grows Stock Holdings in Enovis Co. (NYSE:ENOV)

DAVENPORT & Co LLC raised its position in shares of Enovis Co. (NYSE:ENOVFree Report) by 12.6% during the fourth quarter, HoldingsChannel reports. The firm owned 1,879,425 shares of the company’s stock after purchasing an additional 210,358 shares during the period. DAVENPORT & Co LLC’s holdings in Enovis were worth $105,920,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Tributary Capital Management LLC grew its stake in shares of Enovis by 14.9% during the fourth quarter. Tributary Capital Management LLC now owns 292,626 shares of the company’s stock valued at $16,393,000 after buying an additional 37,858 shares during the last quarter. Pacer Advisors Inc. grew its stake in shares of Enovis by 77.8% during the fourth quarter. Pacer Advisors Inc. now owns 7,463 shares of the company’s stock valued at $418,000 after buying an additional 3,265 shares during the last quarter. Dynamic Advisor Solutions LLC grew its stake in shares of Enovis by 27.4% during the fourth quarter. Dynamic Advisor Solutions LLC now owns 12,057 shares of the company’s stock valued at $678,000 after buying an additional 2,594 shares during the last quarter. Public Employees Retirement System of Ohio grew its stake in shares of Enovis by 48.3% during the third quarter. Public Employees Retirement System of Ohio now owns 65,916 shares of the company’s stock valued at $3,476,000 after buying an additional 21,479 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Enovis by 1.1% during the third quarter. Vanguard Group Inc. now owns 4,897,449 shares of the company’s stock valued at $258,242,000 after buying an additional 51,319 shares during the last quarter. 98.45% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. UBS Group assumed coverage on Enovis in a research note on Monday, January 22nd. They issued a “buy” rating and a $75.00 target price on the stock. Canaccord Genuity Group raised their target price on Enovis from $73.00 to $75.00 and gave the stock a “buy” rating in a research note on Friday, February 23rd. William Blair assumed coverage on Enovis in a research note on Wednesday, January 3rd. They issued an “outperform” rating on the stock. Stephens assumed coverage on Enovis in a research note on Tuesday, February 13th. They issued an “overweight” rating and a $72.00 target price on the stock. Finally, Wells Fargo & Company raised their target price on Enovis from $73.00 to $79.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $75.43.

Read Our Latest Analysis on Enovis

Enovis Stock Down 1.8 %

Enovis stock traded down $1.13 during trading hours on Tuesday, hitting $60.30. 316,577 shares of the stock traded hands, compared to its average volume of 451,427. The firm’s 50-day moving average price is $60.55 and its two-hundred day moving average price is $54.82. The company has a current ratio of 2.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.14. The company has a market cap of $3.31 billion, a PE ratio of -98.85 and a beta of 1.97. Enovis Co. has a one year low of $43.04 and a one year high of $66.14.

Enovis (NYSE:ENOVGet Free Report) last posted its quarterly earnings data on Thursday, February 22nd. The company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.76 by $0.03. The business had revenue of $455.00 million for the quarter, compared to analysts’ expectations of $444.34 million. Enovis had a positive return on equity of 3.84% and a negative net margin of 1.95%. The business’s revenue was up 11.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.72 EPS. On average, research analysts forecast that Enovis Co. will post 2.58 EPS for the current year.

Enovis Company Profile

(Free Report)

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.

See Also

Want to see what other hedge funds are holding ENOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enovis Co. (NYSE:ENOVFree Report).

Institutional Ownership by Quarter for Enovis (NYSE:ENOV)

Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.